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The methylenetetrahydrofolate reductase (MTHFR) variant
c.677C>T (A222V) influences overall survival of patients with
glioblastoma multiforme
Abstract
Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults. Prognosis is poor.
Using a series of 214 GBM patients, we observed an effect of the variant
5,10-methylenetetrahydrofolate reductase (MTHFR) c.677C>T on overall survival. This effect was
strongest in patients younger than 60 years at diagnosis (overall survival, median +/- SE: genotype CC,
13 +/- 1 months; CT, 11 +/- 2 months; TT, 7 +/- 3 months; multivariate Cox regression analysis, Wald =
8.58, p = 0.007). In addition, the MTHFR genotype significantly influenced the overall survival of
patients with a postoperative Karnofsky score >70 (CC, 12 +/- 2 months; CT, 11 +/- 1 months; TT, 10
+/- 4 months; Wald = 5.89, p = 0.015). These data suggest the MTHFR c.677C>T variant is a risk factor
for survival in GBM patients.
The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) is a risk 
factor for overall survival of patients with glioblastoma multiforme  
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Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults. 
Prognosis is poor. In a series of 214 GBM patients we observed an effect of the variant 5,10-
methylenetetrahydrofolate reductase (MTHFR) c.677C>T on the overall survival. In patients 
younger than 60 years of age at diagnosis this effect was strongest (median overall survival in 
months ± standard error, genotype CC: 13±1; CT: 11±2; TT: 7±3; multivariate COX 
regression analysis: Wald=8.58; p=0.007). In addition, the MTHFR genotype significantly 
influenced the overall survival of patients with a postoperative Karnofsky score ≥ 70 (CC: 
12±2; CT: 11±1; TT: 10±4; Wald=5.89; p=0.015). These data suggest the MTHFR c.677C>T 





Methionine metabolism plays an essential role in DNA methylation (Figure 1). The enzyme 5-
methyltetrahydrofolate-homocysteine S-methyltransferase (MTR) catalyses the remethylation 
of homocysteine to methionine. The latter is activated by ATP to S-adenosylmethionine 
(SAM), which provides the methyl groups used for DNA methylation. MTR depends on 
cobalamin (vitamin B12) and 5-methyltetrahydrofolate as cofactors. Most important 
transporter protein of cobalamin is transcobalamin 2 (Tc2), and 5-methyltetrahydrofolate is 
synthesized out of 5,10-methylenetetrahydrofolate by 5,10-methylenetetrahydrofolate 
reductase (MTHFR). Because 5,10-methylenetetrahydrofolate is also directed to synthesis of 
purines and thymidine, MTHFR activity regulates whether an one-carbon unit of 
tetrahydrofolate is utilized for methionine synthesis or for nucleic acid synthesis, and thus for 
DNA synthesis, stability and repair.1  
 
Instability of genomic DNA and impaired DNA methylation are important for the 
development and progression of many tumors.2 Therefore, functional genetic variants of 
methionine metabolism are attractive candidate factors influencing the development and the 
clinical course of human cancers. Indeed, the MTHFR missense variant c.677C>T (A222V) 
and the MTR missense variant c.2756A>G (D919G) have been correlated with the incidence 
of various malignancies.3 Furthermore, functional synergisms have been suggested for the 
variants MTR c.2756A>G and Tc2 c.776C>G (P259R).4 However, only a few studies 
investigated the role of the genetic variants of methionine metabolism as prognostic factor in 
patients with cancer. In the present study we analyzed the effects of four functional 
polymorphisms of the methionine metabolism on the clinical course of 214 GBM patients. 
Although our previous results did not identify the MTHFR c.677C>T variant as a risk factor 




Material and Methods 
Patients 
For this study we analyzed 214 GBM patients (41% female, median age at diagnosis 62 years, 
range 23-80 years, mean age at diagnosis 58 years ± 12 years standard deviation) operated in 
the Dept. of Neurosurgery of the University Hospital Bonn, Germany, between 1994 and 
2003. All histopathological diagnoses were made at the Department of Neuropathology/ 
German Brain Tumor Reference Center at the University of Bonn following the WHO 
criteria.5 A gliosarcoma was diagnosed in 6%, and a giant cell GBM in 3% of cases. The study 
was approved by the Ethics Committee of the Medical Faculty of the University of Bonn. 
Surgical treatment consisted of a total resection in 52%, a subtotal/ partial resection in 43%, 
and a biopsy in 5% of cases. 82% of patients underwent standard fractionated postoperative 
radiotherapy, and 11% were administered additional adjuvant chemotherapy. Thus, adjuvant 
therapy after surgery was categorized as none (surgery only), radiotherapy, and radiation and 
chemotherapy. For 107 patients treatment at tumor relapse could not be ascertained. Hence 
therapy for recurrent tumors was not included in the statistical analysis. Median overall 
survival of all patients ± 1 standard deviation was 10±1 months (95% confidence interval: 9-
11) with 7% censored. 
  
Genotyping 
The genotypes of four missense variants involved in methionine metabolism, MTHFR 
c.677C>T, MTHFR c.1298A>C, MTR c.2756A>G and Tc2 c.776C>G, were determined by 
PCR amplification of genomic DNA prepared from peripheral leukocytes with subsequent 




Log Rank test and Kaplan Meier curves were used to analyze the effect of the four variants on 
overall survival. Due to multiple testing, α was set to 0.0125. The effect of the MTHFR 
variant c.677C>T on overall survival was further investigated by COX regression with 
simultaneous analysis of MTHFR genotype, age, gender, postoperative Karnofsky index, 
extent of resection, and adjuvant therapy as covariables. In additional explorative analyses 
(univariate Log Rank tests and multivariate COX regression analysis with the co-variables 
listed above), the effect of the MTHFR c.677C>T variant was analyzed in subgroups of 
patients defined by adjuvant therapy, age (<60 years vs. ≥60 years, regarding the mean and 
median age at diagnosis in our population and regarding prior studies6; and postoperative 
Karnofsky index (<70 vs. ≥70). 
 
Results 
Log Rank testing demonstrated a significant influence of the MTHFR c.677C>T variant, but 
not of the other three genetic polymorphisms, on overall survival (median survival ± standard 
error in months): CC: 10±1; CT: 10±1; TT: 7±3; Log Rank=9.21; p=0.010 (Table 1).  
Multivariate COX regression including the MTHFR c.677C>T genotype and the clinical data 
revealed younger age (linear variable; Wald=7.10; p=0.008), higher Karnofsky score after 
surgery (linear variable; Wald=21.2; p<0.001) and adjuvant therapy (median survival in 
months ± standard error, none: 2±0.35; radiotherapy: 10±0.36; radiation and chemotherapy: 
11±0.82; Wald=7.81; p=0.005) as important prognostic factors. The extent of resection had a 
statistically significant influence on survival only in the univariate Log Rank test (total 
resection: 10±0.69; subtotal/partial resection: 8±0.85; biopsy: 2±1.58; Log Rank=10.3; 
p=0.006), but not in the multivariate COX regression analysis (Wald=0.68; p=0.447). In the 
multivariate analysis, the effect of the MTHFR c.677C>T genotype on survival was not 
statistically significant, either (Wald=1.01; p=0.316).  
Univariate Log Rank subgroup analysis revealed a highly significant association of the 
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MTHFR c.677C>T polymorphism with survival for patients younger than 60 years of age at 
diagnosis (37% of our study sample): CC: 13±1; CT: 11±2; TT: 7±3 (median survival in 
months ± standard error; Log Rank=9.94; p=0.007; Figure 3). Multivariate COX regression 
analysis showed that these data were robust, i.e. the effect of the MTHFR c.677C>T variant 
on survival in this patient subset was as strong as the effects of some of the clinical co-
variables investigated simultaneously: MTHFR c.677C>T (Wald=8.58; p=0.003), extent of 
resection (Wald=2.10; p=0.148), Karnofsky score after surgery (Wald=12.3; p<0.001), 
adjuvant therapy (Wald=3.32; p=0.086). No significant effect was seen for the MTHFR 
c.677C>T polymorphism for patients >60 years (Wald=0.27; p=0.601).  
Additionally, the MTHFR c.677C>T variant was found to significantly correlate with survival 
in the multivariate analysis among patients with a postoperative Karnofsky score ≥ 70 
regardless of age (c.677CC: 12±2; CT: 11±1; TT: 10±4; Wald=5.89; p=0.015). No such effect 
was seen for patients with a postoperative Karnofsky score < 70 (c.677CC: 5±1; CT: 4±2; TT: 
5±3; Wald=0.01; p=0.951). In none of the subgroups defined by adjuvant therapy the MTHFR 
c.677C>T polymorphism showed any significant correlation with survival.  
 
Discussion 
Overall prognosis for GBM patients is grim with a median survival of only 12-16 months 
even in selected series. However, certain subsets (young age at diagnosis, high extend of 
resection, high Karnofsky score after surgery) of patients can expect to survive for more than 
two years.7 Small therapeutic advances will more likely translate into a clinically relevant 
survival benefit in patients with a relatively good prognosis. Hence the identification of 
prognostic survival factors may help to administer treatment more selectively, i.e. to spare 
those with an adverse prognosis a toxic therapy, and to allow for aggressive treatment in cases 
for which a meaningful prolongation of survival can be achieved.  
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Several tumor mutations have been correlated with the clinical course of GBM patients.8 In 
addition, a few studies have indicated that germline genetic variants may have prognostic 
relevance as well, e.g. the ERCC1 c.8092C>A polymorphism, the deletion of glutathione S-
transferase T1 (GSTT1),9 and a polymorphism in the 5'-untranslated region of the epidermal 
growth factor gene (EGF g.61G>A).10  
The major finding of the present study is an association of the c.677TT genotype of the 
germline variant MTHFR c.677C>T (A222V) with an adverse prognosis of GBM patients. 
Effects of the MTHFR c.677C>T polymorphism were in particular seen in patient subgroups 
with a comparatively good prognosis. In the subgroup of patients under 60 years the 6 months 
difference in median survival between patients homozygous for the MTHFR c.677CC 
genotype versus patients with c.677TT genotype suggests that the effect size contributed by 
the c.677C>T genotype is clinically relevant. Accordingly, the MTHFR c.677TT genotype 
was also associated with a poorer prognosis within the patient subgroup with a postoperative 
Karnofsky score ≥ 70, but not among patients with a worse performance status. The 
association of MTHFR c.677C>T with overall survival did not show any therapy specific 
effect. Given the limitations of any association study, our findings have to be reproduced in an 
independent dataset. 
 
The T-allele of MTHFR c.677C>T, in particular when in homozygous state, leads to a clearly 
reduced enzyme activity.11 Our findings may be explained by an effect on nucleic acid 
synthesis and thus on chromosomal stability.1 In addition, a lack of MTHFR activity can 
cause a reduction of available SAM in several organs including the CNS, and SAM is the key 
methyl group donor for DNA methylation (Figure 1).12 The T-allele of MTHFR c.677C>T 
has already been reported to be associated with global hypomethylation of genomic DNA.13 
Hypomethylation of the O(6)-methylguanine DNA methyltransferase (MGMT) promoter in 
GBM tumor cells has been associated with a shorter survival in GBM patients receiving 
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radiotherapy and treated with temozolomide,14 and also a correlation between the T-allele of 
MTHFR c.677C>T variant and a decreased MGMT promoter hypermethylation has already 
been observed, however, in a series of uterine cervical cancers.15 Thus, it is tempting to 
speculate that differential (tumor) DNA methylation due to MTHFR c.677C>T might 
constitute the molecular basis of the association between the MTHFR c.677C>T 
polymorphism and survival of GBM patients. Accordingly, Cadieux et al. most recently 
demonstrated that the MTHFR c.677C>T variant or a deletion encompassing the MTHFR 
gene locus on chromosome 1p36.3 was associated with global DNA hypomethylation in 
GBM tissue. Tumors with DNA hypomethylation or a MTHFR gene deletion exhibited an 
increased proliferation rate.16 Our study provides the clinical data predicted by these 
observations: Reduced MTHFR activity due to presence of the T-allele of the c.677C>T 
variant is associated with a shorter overall survival. As limitation, we did not know the folate 
intake nor plasma folate levels of the GBM patients, which might have modified the effect of 
the MTHFR genotype on overall survival, as the effect of the c.677C>T variant on MTHFR 
activity is modified by the availability of folate.11,17 
Our findings may have some therapeutic implications. Since the adverse biological effects of 
the T-allele of the MTHFR c.677C>T variant e.g. on DNA methylation may well become 
apparent only in the context of a low folate status,17 folate supplementation or dietary 
strategies influencing methionine and further metabolites of methionine metabolism might be 
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Table 1: Genotypes and overall survival in months (all patients) 
 
MTHFR c.677C>T CC: 10±1 CT: 10±1 TT: 7±3 Log Rank=9.21; p=0.010 
MTHFR c.1298A>C AA: 10±1 AC: 9±1 CC: 14±4 Log Rank=0.60; p=0.742 
MTR c.2756A>G AA: 10±1 AG: 9±1 GG: 8±5 Log Rank=0.07; p=0.967 
Tc2 c.776C>G CC: 8±2 CG: 10±1 GG: 9±2 Log Rank=1.52; p=0.469 
 
Kaplan Meier analysis of the genotypes on overall survival with median survival ± standard 
error in months and results of Log Rank test (two degrees of freedom). Due to multiple 
testing, threshold was defined with α=0.0125. Censored for MTHFR c.677C>T, CC: n=9; CT: 
n=6; TT: n=0. 
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Table 2: MTHFR c.677C>T and overall survival in subgroups 
 c.677CC c.677CT c.677TT Log Rank COX (Wald) 
all patients 10±1 10±1 7±3 9.21; p=0.010 1.01; p=0.316 
patients < 60y 13±1 11±2 7±3 9.94; p=0.007 8.58; p=0.003 
patients ≥ 60y 9±8 8±6 6±5 2.56; p=0.278 0.27; p=0.601 
KPI ≥ 70 12±2 11±1 10±4 5.23; p=0.051 5.89; p=0.015 
KPI < 70 5±1 4±2 5±3 0.42; p=0.896 0.01; p=0.951 
 
The influence of the MTHFR c.677C>T genotype on median overall survival ± standard error 
in months of all patients and of subgroups. Univariate analysis (Log Rank) and multivariate 
analysis with age (not included as covariable in the subgroups defined by age), gender, 
postoperative KPI (not included as covariable in the subgroups defined by KPI), extend of 




Figure 1. Methionine metabolism 
 
In the human methionine metabolism, methionine becomes activated to S-adenosylmethionine 
(SAM) via methionine adenosyltransferase (MAT). SAM is an ubiquitious methyl group 
donor, e.g., for the synthesis of biogenic amines and DNA methylation. The degradation 
product of SAM is S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine per 
homocysteine hydrolase (SAHH). Homocysteine can either be transsulfurated to cystathionine 
and cysteine via vitamin B6-dependent cystathionine beta-synthase (CBS) and cystathionine 
gamma lyase (CGL), or alternatively, homocysteine can be remethylated to methionine. This 
is done by 5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR, also called 
methionine synthase), which needs a derivate of vitamin B12 (methylcobalamin) as well as a 
derivate of folate (5-methyltetrahydrofolate; 5-MTHF) as cofactors. Vitamin B12 is 
transported by transcobalamin 2 (Tc2), and 5-methyltetrahydrofolate is synthesized by 5,10-
methylenetetrahydrofolate reductase (MTHFR) from 5,10-methylenetetrahydrofolate (5,10-
MTHF), which is synthesized from folate by dihydrofolate reductase (DHFR) in two 
subsequent steps.  
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Fig. 1. Human methionine metabolism  
 
 
